Welcure Drugs & Pharmaceuticals Complete Financial Statements

In FYNone, Welcure Drugs & Pharmaceuticals (WELCURE) reported revenue ₹390 Cr, net profit ₹35 Cr and EPS ₹3.30, with a net profit margin of 7.4% and ROE of 1.9%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see WELCURE company profile.

11 Years of Data
2025 - 2015

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 7.41% 2025 data
EBITDA Margin 11.11% 2025 data
Operating Margin 4.00% 2025 data
Return on Assets 0.75% 2025 data
Return on Equity 1.94% 2025 data

Balance Sheet Ratios

Current Ratio 1.48 2025 data
Equity Ratio 38.58% 2025 data
Asset Turnover 0.10 2025 data

WELCURE Revenue, Net Profit & EBITDA — Year-on-Year Growth

WELCURE YoY (March 2025 vs Period) — revenue +1344.4%, net profit +1650.0%, EBITDA +1433.3%, expenses +1333.3%.

Revenue Growth
+1344.4%
Year-over-Year
Net Profit Growth
+1650.0%
Year-over-Year
EBITDA Growth
+1433.3%
Year-over-Year
Expense Growth
+1333.3%
Year-over-Year
Assets Growth
+26600.0%
Year-over-Year
Equity Growth
+10200.0%
Year-over-Year

WELCURE Income Statement — Revenue, EBITDA & Net Profit

Welcure Drugs & Pharmaceuticals revenue ₹390 Cr, EBITDA ₹46 Cr, net profit ₹35 Cr, EPS ₹3.30 (None) — net profit margin 7.4%. Explore WELCURE Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 390 27 0 0 0 0 0 0 0 0 0 0
Expenses 344 24 0 0 0 0 0 0 0 0 0 0
EBITDA 46 3 0 0 0 0 0 0 0 0 0 0
Operating Profit Margin % 8.00% 4.00% 0.00% 0.00% 22.00% 41.00% -12.00% 3.00% -41.00% 31.00% 32.00% 7.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 46 3 0 0 0 0 0 0 0 0 0 0
Tax 11 1 0 0 0 0 0 0 0 0 0 0
Net Profit 35 2 0 0 0 0 0 0 0 0 0 0
Earnings Per Share (₹) 3.30 0.36 -0.13 0.08 0.02 0.05 -0.01 0.00 -0.02 0.02 0.07 0.00

WELCURE Balance Sheet — Assets, Liabilities & Shareholders' Equity

WELCURE total assets ₹267 Cr, total equity ₹103 Cr, total liabilities ₹ Cr (2025) — ROE 1.9%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 267 1 2 0 0 0 0 0 0 0 0
Current Assets 182 0 0 0 0 0 0 0 0 0 0
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0
Capital Work in Progress 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0
Other Assets 267 1 1 0 0 0 0 0 0 0 0
LIABILITIES
Total Liabilities
Current Liabilities 123 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 103 1 2 0 0 0 0 0 0 0 0
Share Capital 112 13 13 12 12 12 12 12 12 12 12
Reserves & Surplus -10 -12 -12 -12 -12 -12 -12 -12 -12 -12 -12

WELCURE Cash Flow Statement — Operating, Investing & Financing

Welcure Drugs & Pharmaceuticals operating cash flow ₹-222 Cr, investing ₹0 Cr, financing ₹222 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -222 0 0 0 0 0 0 0 0 0 0
Investing Activities 0 0 0 0 0 0 0 0 0 0 0
Financing Activities 222 0 0 0 0 0 0 0 0 0 0
Net Cash Flow 0 0 0 0 0 0 0 0 0 0 0